Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lysine-specific demethylase 4A (KDM4A), also known as JMJD2A, is a member of the Jumonji domain 2 (JMJD2) family of histone demethylases. It functions as an Fe(II)- and 2-oxoglutarate-dependent oxygenase that specifically demethylates trimethylated and dimethylated lysine 9 and lysine 36 residues on histone H3 (H3K9me2/3 and H3K36me2/3). Through this epigenetic modification, KDM4A plays a critical role in chromatin remodeling, transcriptional regulation, cell cycle progression, and cellular senescence. It acts as a co-regulator of transcription, often cooperating with oncogenes like Ras and transcription factors like androgen receptor (AR) to promote cell proliferation and survival.
In human diseases, KDM4A is widely recognized as an oncogenic driver and is overexpressed in various malignancies, including prostate, lung, breast, colorectal, and endometrial cancers, where it drives tumor progression, metastasis, and drug resistance. It has also been implicated in inflammatory processes, such as macrophage polarization in atherosclerosis, and viral reactivation. Consequently, KDM4A has emerged as an attractive therapeutic target. Small-molecule inhibitors, such as the pan-KDM4 inhibitor zavondemstat (TACH101), have entered clinical trials for advanced solid tumors. However, drug development faces challenges, including selectivity among KDM4 isoforms and other JmjC demethylases, as well as recent revelations that some prominent KDM4 inhibitors (like QC6352 and zavondemstat) exhibit highly potent off-target activity against dihydroorotate dehydrogenase (DHODH).
Inhibition of histone demethylase activity by competing with the 2-oxoglutarate (2-OG) co-substrate, chelating the active-site catalytic iron (Fe(II)) ion, or disrupting histone substrate binding.
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lysine-specific demethylase 4A (KDM4A) (KDM4A).